
News|Articles|July 1, 2009
FDA Pipeline preview, July 2009 (bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, paclitaxel)
Recent FDA action (through July 2009) related to bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, and paclitaxel
Advertisement
Complete response
Recommended for approval
Fast-track designations
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Real-World Data Shows Vision Decline as Copay Programs Run Dry | AAO 2025
2
In Complement Inhibition Debate, Game Change Goes Against Too Little, Too Late | AAO 2025
3
The Next Breakthrough in Schizophrenia Could be a Digital Therapeutic
4
AI and Ophthalmology: A Nearly Picture Perfect Kinda Match | AAO 2025
5